全文获取类型
收费全文 | 3505篇 |
免费 | 190篇 |
国内免费 | 41篇 |
专业分类
耳鼻咽喉 | 20篇 |
儿科学 | 91篇 |
妇产科学 | 56篇 |
基础医学 | 446篇 |
口腔科学 | 123篇 |
临床医学 | 674篇 |
内科学 | 812篇 |
皮肤病学 | 45篇 |
神经病学 | 291篇 |
特种医学 | 179篇 |
外科学 | 279篇 |
综合类 | 49篇 |
一般理论 | 1篇 |
预防医学 | 233篇 |
眼科学 | 31篇 |
药学 | 199篇 |
中国医学 | 4篇 |
肿瘤学 | 203篇 |
出版年
2023年 | 16篇 |
2022年 | 19篇 |
2021年 | 53篇 |
2020年 | 26篇 |
2019年 | 40篇 |
2018年 | 45篇 |
2017年 | 36篇 |
2016年 | 40篇 |
2015年 | 85篇 |
2014年 | 66篇 |
2013年 | 111篇 |
2012年 | 149篇 |
2011年 | 144篇 |
2010年 | 95篇 |
2009年 | 105篇 |
2008年 | 160篇 |
2007年 | 172篇 |
2006年 | 171篇 |
2005年 | 167篇 |
2004年 | 193篇 |
2003年 | 175篇 |
2002年 | 129篇 |
2001年 | 120篇 |
2000年 | 81篇 |
1999年 | 63篇 |
1998年 | 125篇 |
1997年 | 109篇 |
1996年 | 91篇 |
1995年 | 84篇 |
1994年 | 65篇 |
1993年 | 65篇 |
1992年 | 64篇 |
1991年 | 55篇 |
1990年 | 55篇 |
1989年 | 51篇 |
1988年 | 61篇 |
1987年 | 42篇 |
1986年 | 42篇 |
1985年 | 44篇 |
1984年 | 40篇 |
1983年 | 29篇 |
1982年 | 17篇 |
1981年 | 20篇 |
1980年 | 21篇 |
1979年 | 31篇 |
1978年 | 18篇 |
1977年 | 14篇 |
1976年 | 16篇 |
1974年 | 12篇 |
1969年 | 13篇 |
排序方式: 共有3736条查询结果,搜索用时 15 毫秒
61.
Deininger M Pönisch W Krahl R Leiblein S Edel E Lange T Fiedler F Freund M Franke A Pasold R von Grünhagen U Herold M Dölken G Hoffmann FA Uhle R Schultze W Steglich J Schwarzer A Richter P Winkelmann C Kettner E Dachselt K Subert R Schwalbe E Doepper J Helbig W Niederwieser D;East German Study Group Haematology/Oncology 《Bone marrow transplantation》2001,27(11):1125-1132
Mobilised peripheral blood stem cells are widely used for autografting in patients with chronic myeloid leukaemia (CML) and it is generally thought that a high proportion of Ph-negative progenitor cells in the graft is desirable. We report here the results of 91 stem cell mobilisations performed with various chemotherapy regimens followed by G-CSF. We show that mobilisation of Ph-negative cells is possible after diagnosis as well as in advanced stages of the disease. The yield of Ph-negative cells is highly dependent on the chemotherapy regimen: while the combination of idarubicin and cytarabin for 3-5 days (IC3-5) mobilised Ph-negative cells in most patients, high-dose cyclophosphamide was ineffective. Mobilisation of Ph-negative progenitor cells after IC3 was at least as effective as after IC5; however, less apheresis sessions were required, and toxicity was much reduced after IC3. Compared to historical controls, IC was equally effective as the widely used ICE/miniICE (idarubicin, cytarabin, etoposide) protocol. No correlation was found between graft quality and the cytogenetic response to subsequent treatment with interferon-alpha. We conclude that IC3 is an effective and well-tolerated regimen for mobilising Ph-negative cells that compares well with more aggressive approaches such as IC5 and ICE/miniICE. 相似文献
62.
Hiddemann W Spiekermann K Buske C Feuring-Buske M Braess J Haferlach T Schoch C Kern W Schnittger S Berdel W Wörmann B Heinecke A Sauerland C Büchner T;German AML Cooperative Group 《Critical reviews in oncology/hematology》2005,56(2):235-245
Genetic and molecular techniques have provided increasing insights into the biology of acute myeloid leukemia (AML). These investigations showed that AML is not a homogeneous disease but a heterogeneous group of biologically different subentities. These subentities are currently primarily defined by cytogenetics by which three main subgroups can be discriminated: AML with balanced translocations, AML with unbalanced aberrations and AML without cytogenetically detectable aberrations. Within the latter group molecular alterations are identified in more than half of cases such as NPM mutations, FLT3 mutations, MLL duplications and mutations of CEBP-alpha. The clinical meaning of these findings is illustrated by substantial differences in response to therapy and long-term outcome. As demonstrated by the recent multicenter trial of the German AML Cooperative Group (AMLCG) and other studies intensification of induction therapy may improve the results in distinct subtypes but fails to do so in others. Therefore, new strategies need to be explored which incorporate the knowledge about the biology of AML to develop biology adapted treatment strategies. This process has just begun and is predominantly determined by the availability of new agents and their evaluation in clinical phase I and II studies. A variety of targets are currently explored and some trials have yielded promising results already. The step towards a biology adapted treatment of AML is long and requires the combined efforts of researchers, clinicians and the pharmaceutical industry. The first steps towards this goal have been taken and give rise to the hope for more effective and more specific therapies of AML. 相似文献
63.
Brosteanu O Hasenclever D Loeffler M Diehl V;German Hodgkin's Lymphoma Study Group 《Annals of hematology》2004,83(3):176-182
Chemotherapy-treated patients with advanced Hodgkins disease (HD) differ considerably in acute hematotoxicity. Hematotoxicity may be indicative of pharmacological and metabolic heterogeneity. We hypothesized that low hematotoxicity might correlate with reduced systemic dose and thus reduced disease control. A total of 266 patients with advanced HD treated with cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, vinblastine, and dacarbazine (COPP-ABVD) were analyzed (HD6 trial of the German Hodgkins Lymphoma Study Group). The reported WHO grade of leukocytopenia was averaged over chemotherapy cycles given and weighted with the reciprocal dose intensity of the corresponding cycle. The low and high toxicity groups were defined in retrospect as having had an averaged WHO grade of leukocytopenia 2.1 and >2.1, respectively. The independent impact of low hematological toxicity on freedom from treatment failure (FFTF) was assessed multivariately adjusting for the international prognostic score for advanced HD. The results were validated in two independent cohorts [181 patients treated with COPP-ABVD (HD9-trial) and 250 patients treated with COPP-ABV-ifosfamide, methotrexate, etoposide, and prednisone (IMEP) (HD6 trial)]. The 5-year FFTF rates were 68% for patients with high toxicity vs 47% for patients with low toxicity [multivariate relative risk (RR) 2.0, 95% confidence interval (CI) 1.4–3.0, p=0.0002]. Patients with low toxicity received significantly higher nominal dose (p=0.02) and dose intensity (p<0.0001). This finding was confirmed in both validation cohorts (multivariate RR 2.1, 95% CI 1.2–3.8, p=0.01 and RR 1.5, 95% CI 1.01–2.26, p=0.04, respectively). Patients with low hematotoxicity have significantly higher failure rates despite higher doses and dose intensity. Hematotoxicity is an independent prognostic factor for treatment outcome. This observation suggests a strategy of individualized dosing adapted to hematotoxicity.The authors listed above wrote this contribution on behalf of the German Hodgkins Lymphoma Study Group 相似文献
64.
Sánchez-Vázquez R Briseño-Rodríguez G Cardona-Muñoz EG Gálvez-Gastélum FJ Totsuka-Sutto SE Garcia-Benavides L 《Angiology》2008,59(1):64-71
Venous ulcers are the most common form of leg ulcers, which induce lesion because of the loss of substances deposited on the damaged skin. Isosorbide dinitrate is a vasodilator with effects on both arteries and veins and induces opening of vascular layers. The objective is to study the effects of isosorbide dinitrate-spray in patients with chronic venous ulcers. Forty-five patients of both sexes with chronic venous ulcers were randomized to receive isosorbide dinitrate or placebo sprays daily for 3 months. The ulcers were measured and clinical characteristics were taken every 15 days during the treatment. Patients treated with isosorbide dinitrate showed an improvement of the ulcerated area (71.29%) compared with patients treated with placebo (54.35%). The histopathological study indicated an increment in the number of hypertrophic and hyperplasic capillaries. Macroscopically, the isosorbide dinitrate-treatment showed the best results, but it was only during the first 6 weeks of treatment. Patients with chronic venous ulcer receiving isosorbide dinitrate spray showed improvement. 相似文献
65.
Kröger N Einsele H Wolff D Casper J Freund M Derigs G Wandt H Schäfer-Eckart K Wittkowsky G Schmitz N Krüger W Zabelina T Renges H Ayuk F Krüll A Zander A;German Study-group Multiple Myeloma 《Bone marrow transplantation》2003,31(11):973-979
We investigated toxicity and efficacy of in vivo T-cell depletion with anti-thymocyte globulin (ATG) as part of an intensified myeloablative conditioning regimen followed by allogeneic stem cell transplantation in patients with advanced multiple myeloma. The conditioning regimen consisted of modified total body irradiation, busulfan and cyclophosphamide (n=15) or in the case of prior dose-limiting radiotherapy of busulfan and cyclophosphamide (n=3). The median age was 44 years (range, 29-53) and the median time from diagnosis to transplant was 12 months (range, 6-144). Grade II-IV acute graft-versus-host disease (GvHD) occurred in six patients (35%). Severe grade III/IV GvHD developed in one patient (6%). Three patients died of therapy-related causes (17%). A complete remission (CR) with negative immunofixation after allogeneic transplantation was seen in eight of the evaluable patients (53%). After a median follow-up of 41 months (range, 8-84), the estimated overall survival at 6 years for all patients is 77% (CI 95%: 58-96%). The estimated progression-free survival at 6 years for all patients is 31% (CI 95%: 2-59%) and 46% (CI 95%: 9-83%) for patients with CR. In vivo T-cell depletion with ATG resulted in a low rate of severe GvHD with low treatment-related mortality, and a substantial number of long-term survivors. 相似文献
66.
N. Sadick Deborah Campano German Ph. A. McHale J. C. Greenfield Jr. M.D. N. M. Kredich 《Basic research in cardiology》1985,80(3):280-290
Summary The purpose of this study was to test the hypothesis that L-homocysteine thiolactone (L-HCTL), through its reaction with adenosine to formS-adenosylhomocysteine, may modulate myocardial functional and reactive hyperemic responses. Reactive hyperemic responses to 10-sec occlusions or 400-msec diastolic occlusions of the circumflex coronary artery and functional hyperemic responses to ventricular extra-activations were studied in a chronic heart-blocked dog preparation during a control period and following L-HCTL (40 mg/kg). In two additional dogs multiple venous blood samples and left ventricular myocardial biopsies were obtained following L-HCTL to measure changes in plasma homocysteine and tissueS-adenosylhomocysteine. Despite a 75-fold increase in peak plasma homocysteine and a 26-fold increase in tissueS-adenosylhomocysteine, L-HCTL did not alter myocardial functional and reactive hyperemic responses.The rapid increase in myocardialS-adenosylhomocysteine confirmed cellular entry of homocysteine and its reaction with endogenous adenosine. The failure of L-HCTL to alter functional and reactive hyperemic responses suggests that either such treatment does not affect myocardial release of adenosine or that adenosine is not an important regulator of coronary flow.Supported in part by the National Institutes of Health Grants HL 18468 and AM 12828 and the Medical Research Service of the Veterans Administration. Dr. Sadick is a recipient of an Overseas Research Fellowship from the Australian National Heart Foundation. Parts of this work were presented at the 56th Scientific Sessions, American Heart Association, Anaheim, California, November, 1983. 相似文献
67.
Can F. Koyuncu Cheng Lu Kaustav Bera Zelin Zhang Jun Xu Paula Toro German Corredor Deborah Chute Pingfu Fu Wade L. Thorstad Farhoud Faraji Justin A. Bishop Mitra Mehrad Patricia D. Castro Andrew G. Sikora Lester D.R. Thompson R.D. Chernock Krystle A. Lang Kuhs Jingqin Luo Vlad Sandulache David J. Adelstein Shlomo Koyfman James S. Lewis Jr. Anant Madabhushi 《The Journal of clinical investigation》2021,131(8)
BACKGROUNDPatients with p16+ oropharyngeal squamous cell carcinoma (OPSCC) are potentially cured with definitive treatment. However, there are currently no reliable biomarkers of treatment failure for p16+ OPSCC. Pathologist-based visual assessment of tumor cell multinucleation (MN) has been shown to be independently prognostic of disease-free survival (DFS) in p16+ OPSCC. However, its quantification is time intensive, subjective, and at risk of interobserver variability.METHODSWe present a deep-learning–based metric, the multinucleation index (MuNI), for prognostication in p16+ OPSCC. This approach quantifies tumor MN from digitally scanned H&E-stained slides. Representative H&E-stained whole-slide images from 1094 patients with previously untreated p16+ OPSCC were acquired from 6 institutions for optimization and validation of the MuNI.RESULTSThe MuNI was prognostic for DFS, overall survival (OS), or distant metastasis–free survival (DMFS) in p16+ OPSCC, with HRs of 1.78 (95% CI: 1.37–2.30), 1.94 (1.44–2.60), and 1.88 (1.43–2.47), respectively, independent of age, smoking status, treatment type, or tumor and lymph node (T/N) categories in multivariable analyses. The MuNI was also prognostic for DFS, OS, and DMFS in patients with stage I and stage III OPSCC, separately.CONCLUSIONMuNI holds promise as a low-cost, tissue-nondestructive, H&E stain–based digital biomarker test for counseling, treatment, and surveillance of patients with p16+ OPSCC. These data support further confirmation of the MuNI in prospective trials.FUNDINGNational Cancer Institute (NCI), NIH; National Institute for Biomedical Imaging and Bioengineering, NIH; National Center for Research Resources, NIH; VA Merit Review Award from the US Department of VA Biomedical Laboratory Research and Development Service; US Department of Defense (DOD) Breast Cancer Research Program Breakthrough Level 1 Award; DOD Prostate Cancer Idea Development Award; DOD Lung Cancer Investigator-Initiated Translational Research Award; DOD Peer-Reviewed Cancer Research Program; Ohio Third Frontier Technology Validation Fund; Wallace H. Coulter Foundation Program in the Department of Biomedical Engineering; Clinical and Translational Science Award (CTSA) program, Case Western Reserve University; NCI Cancer Center Support Grant, NIH; Career Development Award from the US Department of VA Clinical Sciences Research and Development Program; Dan L. Duncan Comprehensive Cancer Center Support Grant, NIH; and Computational Genomic Epidemiology of Cancer Program, Case Comprehensive Cancer Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH, the US Department of VA, the DOD, or the US Government. 相似文献
68.
Carla Palleis MD Matthias Brendel MD Anika Finze Endy Weidinger MD Kai Bötzel MD Adrian Danek MD Leonie Beyer MD Alexander Nitschmann Maike Kern Gloria Biechele Boris-Stephan Rauchmann MD Jan Häckert MD Matthias Höllerhage MD Andrew W. Stephens MD PhD Alexander Drzezga MD Thilo van Eimeren MD Victor L. Villemagne MD Andreas Schildan PhD Henryk Barthel MD Marianne Patt PhD Osama Sabri MD German Imaging Initiative for Tauopathies Peter Bartenstein MD Robert Perneczky MD Christian Haass PhD Johannes Levin MD Günter U. Höglinger MD 《Movement disorders》2021,36(9):2104-2115
69.
William Matthew Negreiros Faris Z. Jamjoom German Gallucci Adam Hamilton 《The Journal of prosthetic dentistry》2021,125(3):387-391
A method for creating a complete-arch digital trial tooth arrangement for completely edentulous patients is described. The technique demonstrates an effective way to reproduce the dental and gingival anatomies by using a free 3D modeling software program. This cost-effective, time-saving, and versatile method allows dental professionals to digitally plan challenging treatments for completely edentulous patients. The technique can also be used to fabricate diagnostic prostheses and implant-supported interim prostheses. 相似文献
70.
Prevalence of Cardiac Diastolic Dysfunction in HIV-Infected Patients: Results of the HIV-HEART Study
The German Competence Network Heart Failure the German Competence Network for HIV AIDS 《HIV clinical trials》2013,14(3):156-162
AbstractPurpose: Antiretroviral therapy has improved the prognosis for many individuals with HIV infection. Consequently, HIV infection has become a chronic and manageable disease with increased risk of cardiovascular disease. Isolated diastolic dysfunction (DD) may be the first indication of underlying cardiac disease and an early marker of coronary artery disease. Our aim was to assess the prevalence of DD in HIV-infected patients. Methods: In this cross-sectional cohort study, 698 unselected patients were included. All subjects underwent two-dimensional transthoracic echocardiography with tissue Doppler imaging. Results: The prevalence of DD among the HIV-infected patients was 48%. Patients with DD were characterized by older age, higher body mass index, higher total cholesterol, arterial hypertension, and diabetes mellitus. Diabetes mellitus and arterial hypertension were associated with approximately four times the risk for DD (odds ratio [OR] 3.9, 95% CI 1.65–9.17; OR 3.8, 95% CI 2.49–5.71, respectively). Persons with hyperlipidemia were approximately one and a half times more likely to have DD than those without hyperlipidemia (OR 1.5, 95% CI 1.12–2.07). Conclusions: In our study, an impressive high prevalence of DD in HIV-infected patients was demonstrated. Traditional cardiovascular risk factors substantially contributed to the development of DD in the HIV-infected cohort. 相似文献